Dr. Arthur L. Horwich appointed to the Scientific Advisory Board of Plex Pharmaceuticals

News provided by

Plex Pharmaceuticals

11 Aug, 2016, 09:30 ET

SAN DIEGO, Aug. 11, 2016 /PRNewswire/ -- Plex Pharmaceuticals (registered as CalAsia Pharmaceuticals, Inc.) is pleased to announce the appointment of Dr. Arthur L. Horwich, MD as a member of the Scientific Advisory Board. Dr. Horwich is The Sterling Professor of Genetics and Pediatrics in the Department of Genetics, Yale University School of Medicine and is a Howard Hughes Medical Institute Investigator. He is a recipient of numerous awards, including The Albert and Mary Lasker Award for Basic Medical Research, The Rosenstiel Award for Distinguished Work in Basic Medical Science, The Shaw Prize in Life Science and Medicine and the 2016 Albany Medical Center Prize in Medicine and Biomedical Research.

"We are delighted to have Dr. Horwich join Plex," said Dr. Allan E. Rubenstein, MD, Chairman. "His strong experience in basic biology and translational research in the field of molecular chaperones combined with clinical expertise will greatly accelerate Plex's goal toward advancing our early stage drug discovery programs into identification of preclinical and clinical candidates as treatments for neurodegenerative disorders."

About Plex Pharmaceuticals:  Plex Pharmaceuticals is an early stage biotechnology company which is focusing its drug discovery expertise on diseases caused by protein misfolding:  ALS, Parkinson's disease and cataracts.  CalAsia Pharmaceuticals, the predecessor to Plex Pharmaceuticals, was founded in 2009 and raised almost $3,000,000 in non-dilutive funding from the NIH and the Michael J. Fox Foundation to support its efforts in fragment-based screening and structure-based drug design. Plex's ALS effort is built around the work of Scientific Advisory Board member Dr. Arthur Horwich, Yale University School of Medicine.  Dr. Horwich was one of the co-discoverers of the protein chaperone machinery, for which he received a Lasker Award. Plex Pharmaceuticals additionally has a development program for Dengue, West Nile and Zika antiviral drugs which has also received support from the NIH and has worked on a novel brain-penetrant heat shock protein 90 (HSP90) inhibitor for glioblastoma.

Contact:
Sridhar Prasad
Office: 1-858-587-8800
Cell: 1-858-733-0858
[email protected]

SOURCE Plex Pharmaceuticals

PRN Top Stories Newsletters

Sign up to get PRN’s top stories and curated news delivered to your inbox weekly!

Thank you for subscribing!

By signing up you agree to receive content from us.
Our newsletters contain tracking pixels to help us deliver unique content based on each subscriber's engagement and interests. For more information on how we will use your data to ensure we send you relevant content please visit our PRN Consumer Newsletter Privacy Notice. You can withdraw your consent at any time in the footer of every email you'll receive. Mit Ihrer Anmeldung erklären Sie sich damit einverstanden, Inhalte von uns zu erhalten.
Unsere Newsletter enthalten Zählpixel, die die Lieferung einzigartiger Inhalte in Bezug auf das Abonnement und die Interessen der einzelnen Abonnenten ermöglichen. Weitere Informationen über die Verwendung Ihrer Daten im Hinblick auf die Zusendung von relevanten Inhalten, finden Sie in unserer PRN Consumer Newsletter Privacy Notice. Ihre Zustimmung können Sie jederzeit in der Fußzeile jeder erhaltenen E-Mail widerrufen. En vous inscrivant à la newsletter, vous consentez à la réception de contenus de notre part.
Notre newsletter contient des pixels espions nous permettant la fourniture à chaque abonné, d’un contenu unique en lien avec ses souscriptions et intérêts. Pour de plus amples informations sur l’utilisation faite de vos données en vue de l’envoi des contenus concernés, nous vous invitons à consulter la politique de confidentialité disponible à partir du lien suivant PRN Consumer Newsletter Privacy Notice. Vous pouvez à tout moment revenir sur votre consentement par le biais des informations situées au bas de chaque e-mail reçu. Регистрирайки се, Вие се съгласявате да получавате информационно съдържание от нас. Нашите бюлетини съдържат проследяващи пиксели, които ни помагат да предоставяме уникално съдържание въз основа на ангажираността и интересите на всеки абонат. За повече информация относно начина, по който ще използваме Вашите данни, за да гарантираме, че Ви изпращаме подходящо съдържание, моля, направете справка с нашето Уведомление за поверителност на потребителския бюлетин на PRN. Можете да оттеглите съгласието си по всяко време в долния колонтитул на всеки от имейлите, които ще получите.